A recent cost-effectiveness analysis evaluated treatments for relapsed or refractory multiple myeloma from a United States health system perspective. READ MORE

News

A monotherapy produced better overall survival outcomes when compared with a standard combination regimen in patients with heavily pretreated multiple myeloma, according to a recent study.

READ MORE

Receipt of treatment for multiple myeloma varies greatly among racial or ethnic minorities.

READ MORE

Elevated C-reactive protein prior to autologous stem cell transplantation identifies a high-risk population in patients with multiple myeloma.

READ MORE

Heart failure, angina, and other cardiovascular adverse events occur more frequently in patients with relapsed multiple myeloma receiving a conventional therapy.

READ MORE

Special Reports

The Special Report, "Clinical Pathways to Address the Challenges of Treatment Resistance and Relapse in Multiple Myeloma," reviews the challenges associated with different phases of treatment for multiple myeloma and how clinical pathways can support physicians’ decision-making.

READ MORE

The Special Report, "Clinical Pathways to Address the Challenges of Treatment Resistance and Relapse in Multiple Myeloma," reviews the challenges associated with different phases of treatment for multiple myeloma and how clinical pathways can support physicians’ decision-making.

READ MORE

This report reviews the complex nature of multiple myeloma treatment, the current landscape of clinical practice guidelines and treatment pathways, and economic considerations for treatment.

READ MORE